Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

US mRNA specialist Moderna presented its fourth quarter and annual financial results on Friday, along with its 2025 guidance.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...